Metride Plus 2 Tablet SR is a fixed-dose combination medication containing Glimepiride (2mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. This formulation synergistically targets multiple pathophysiological defects associated with type 2 diabetes to improve glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which improves insulin sensitivity in adipose tissue, muscle, and the liver. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting stable plasma concentrations and reducing dosing frequency, which may enhance patient adherence. Metride Plus 2 Tablet SR is prescribed as an adjunct to diet and exercise when monotherapy is insufficient to achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly and assess renal and hepatic function during therapy. Caution is advised in patients with heart failure, hepatic impairment, or risk of lactic acidosis. This combination therapy offers a comprehensive approach to managing hyperglycemia in type 2 diabetes.